Fitch Affirms Rating for Thermo Fisher Scientific | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Fitch Rating today affirmed its "A-" issuer default rating for Thermo Fisher Scientific, following the firm's announcement that it plans to acquire allergy and autoimmune diagnostics firm Phadia for €2.47 billion ($3.5 billion).

The ratings apply to $4.3 billion of debt outstanding as of April 2. The ratings outlook on Thermo Fisher is "Stable," Fitch said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.